IDEAYA Biosciences, Inc.
IDYA
$33.09
$0.260.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 55.37% | -- | -- | -- | 78.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.37% | -- | -- | -- | 78.48% |
| Cost of Revenue | -38.22% | 45.21% | 36.11% | 65.60% | 261.58% |
| Gross Profit | 43.14% | 318.44% | -36.11% | -65.60% | -282.18% |
| SG&A Expenses | 72.04% | 68.25% | 40.27% | 64.43% | 54.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.23% | 48.57% | 36.78% | 65.41% | 229.71% |
| Operating Income | 34.39% | 262.13% | -36.78% | -65.41% | -243.87% |
| Income Before Tax | 36.10% | 330.11% | -46.84% | -82.40% | -283.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.10% | 330.11% | -46.84% | -82.40% | -283.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.10% | 330.11% | -46.84% | -82.40% | -283.78% |
| EBIT | 34.39% | 262.13% | -36.78% | -65.41% | -243.87% |
| EBITDA | 34.63% | 264.53% | -36.98% | -66.24% | -247.72% |
| EPS Basic | 36.99% | 324.01% | -29.40% | -55.04% | -186.70% |
| Normalized Basic EPS | 40.12% | 324.03% | -29.38% | -55.06% | -152.05% |
| EPS Diluted | 36.73% | 321.19% | -29.40% | -55.04% | -186.70% |
| Normalized Diluted EPS | 40.12% | 321.10% | -29.38% | -55.06% | -152.05% |
| Average Basic Shares Outstanding | 1.42% | 2.71% | 13.48% | 17.64% | 33.86% |
| Average Diluted Shares Outstanding | 1.42% | 4.06% | 13.48% | 17.64% | 33.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |